CONCLUSIONS: Despite its rare occurrence, our findings confirm sRCC variant histology being a strong predictor for inferior outcomes in mRCC treated with targeted therapies. Our findings support the thesis of a reduced response to antiangiogenic therapies due to an increased resistance in sRCC compared to ccRCC. METHODS: We collected data of 398 patients with mRCC at our academic center. Patients with previous immunotherapy, metastasectomy only treatment and missing data were excluded. A final cohort of 262 pts. remained for analyses. Patients received either CN and subsequent TKI or immediate TKI treatement. Differences in patient characteristics and outcomes were analyzed using descriptive analytics, Kaplan-Meier estimations and uni-and multivariable Cox regression proportional with regards to CN administration.
INTRODUCTION AND OBJECTIVES: While cytoreductive nephrectomy (CN) was standard of care for a decade, the results of the CARMENA trial have challenged the role of CN in the multi-kinase receptor inhibitor (TKI) era. However, CARMENA focused on patients with MSKCC intermediate and poor prognosis scores. We sought to investigate the role of CN in a real-world metastatic renal cell carcinoma (mRCC) population.
METHODS: We collected data of 398 patients with mRCC at our academic center. Patients with previous immunotherapy, metastasectomy only treatment and missing data were excluded. A final cohort of 262 pts. remained for analyses. Patients received either CN and subsequent TKI or immediate TKI treatement. Differences in patient characteristics and outcomes were analyzed using descriptive analytics, Kaplan-Meier estimations and uni-and multivariable Cox regression proportional with regards to CN administration.
RESULTS: The median age of our cohort was 62 yrs., 193 (74%) pts. were male and 214 (82%) had clear-cell RCC (ccRCC) histology. In total, 105 pts. (40.1%) received CN and 157 (59.9%) were treated with TKI therapy immediately. There was no difference in type of TKIs or lines of treatment between both groups. The majority of patients received sunitinib (66%) or sorafenib (20%) as first line treatment. According to the MSKCC risk score, 22.5%, 58.4% and 19.1% patients fell into the good, intermediate and poor prognosis group, respectively. Patients treated with CN were statistically significant younger and had more advanced tumor stages, higher MSKCC risk scores and more frequently sarcomatoid tumor features (all pï‚£0.004). At a median follow-up of 33 months, in overall unadjusted Kaplan-Meier analyses pts. with CN had significantly worse overall, cancer-specific (both p[0.004) and progression-free survival (PFS; p[0.003), respectively. In multivariable analyses, that adjusted for standard clinic-pathologic factors CN was not an independent predictor for inferior outcomes. In contrast, higher ECOG score, non-ccRCC, sarcomatoid tumor features, and less favorable MSKCC risk score were independent predictors for inferior survival for all three endpoints (p-valuesï‚£0.022). In addition, higher T-stage was associated with worse overall survival (p[0.014) and the number of TKI lines was associated with PFS (p[0.001).
CONCLUSIONS: There is no difference in overall, cancerspecific and progression-free survival with or without CN in our realworld series including pts. with good MSKCC risk scores. Our results warrant confirmation in the new era including checkpoint inhibitor immunotherapy. is associated with prolonged disease-free survival and occasional long-term cure in selected patients. However, the majority of existing data is from the immunotherapy era. Whether complete metastasectomy (CM) remains beneficial among contemporary patients, with more effective systemic therapies available, has not been well studied. Therefore, we examined outcomes of patients treated with CM in the era of targeted therapy and checkpoint blockade availability.
METHODS: We queried our institutional nephrectomy registry to identify patients treated with radical or partial nephrectomy for unilateral, sporadic RCC whose first occurrence of distant metastases occurred between 2006-2017. Patients were classified according to whether or not they underwent complete surgical resection of all sites of metastatic disease. Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method, and associations of clinicopathologic features with time to death from RCC were assessed using Cox proportional hazards models.
RESULTS: A total of 586 patients were identified, including 158 treated with CM. Median follow up after diagnosis of metastases was 3.9 years, during which time 403 patients died, including 345 from RCC. CM patients were more likely to have metastases diagnosed > 1 year after nephrectomy and to have a solitary site of metastasis than those without CM (p<0.001 for both). Of the CM patients, 147 (93%) did not require systemic therapy (targeted therapy or immunotherapy) for their index metastatic lesion(s). Two-year CSS was significantly greater for patients with CM than for those without (84% vs. 54%, p<0.001). After adjusting for age, sex, and the timing, number, and location of metastases, CM was associated with a significantly reduced likelihood of death from RCC (HR 0.42, p<0.001) .
CONCLUSIONS: Complete surgical resection of metastases from RCC is associated with improved CSS in the contemporary era. CM should continue to be considered a viable treatment option for select patients with metastatic RCC.
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MP25-07 NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTIVE BIOMARKER FOR RESPONSE TO NIVOLUMAB IN ASIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Yukari Bando*, Mariko Sakamoto, Yasuyoshi Okamura, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa, Kobe, Japan INTRODUCTION AND OBJECTIVES: Nivolumab, a programmed cell death protein-1 (PD-1) antibody, is one of the most effective therapeutic agents for advanced renal cell carcinoma (RCC). Biomarkers predicting response to this treatment are needed to better select patients most likely to benefit. Neutrophil-to-lymphocyte ratio (NLR) is a prognostic and predictive biomarker in various malignancies. We sought to identify predictive markers of nivolumab response in patients with advanced RCC, including NLR.
METHODS: A retrospective review was performed for 109 consecutive patients with metastatic or unresectable RCC treated with nivolumab from December 2016 to September 2018 at our institution and seven related institutions. Landmark analysis was conducted to explore the prognostic value of NLR at baseline on overall survival. Cox and logistic regression models allowed for adjustment of age, platelet count, IMDC risk classification, experience of cytoreductive
